Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NowPatient vs Obu Health

NowPatient
Graded #217

Higher grade

vs+5.600000000000001
Obu Health
Graded #332

Lower grade

The verdict

NowPatient takes it — 65.5/100 to 59.9/100.

NowPatient grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueObu Health +9
35
44
Dose & formulationNowPatient +29
93
64
Clinical oversightNowPatient +2
86
84
Labs & monitoringNowPatient +1
54
53
FulfillmentObu Health +4
70
74
Contract termsNowPatient +24
55
31
NowPatient · left barObu Health · right bar

The numbers

MetricNowPatientObu Health
WeighScore65.5/10059.9/100
GradeCC
Scorecard rank#217#332
Semaglutide$1,349/mo (brand Wegovy)$190/mo (starting dose, plus a separate fee, compounded)
Tirzepatide$1,069/mo (brand Mounjaro, promotional rate)$239/mo (starting dose, plus a separate fee, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
NowPatient

Graded #217 · C

Strengths

  • Free telehealth consultation — you only pay for the medication
  • Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
  • One of the few platforms offering Wegovy in both injection and oral pill form
  • No compounded options — every drug is FDA-approved brand-name

Where it loses points

  • Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
  • No compounded semaglutide or tirzepatide (usually the cheaper route)
  • State availability determined during intake, not shown upfront
  • Does not offer Foundayo (orforglipron)
Obu Health

Graded #332 · C

Strengths

  • LegitScript-certified with publicly displayed ID (44206977)
  • Two named 503A compounding-pharmacy partners (Manifest Pharmacy SC + RX Compounding Store FL) — transparency above category baseline
  • Lower advertised semaglutide starting price ($190) than most multi-product peer platforms
  • Multi-product offering (GLP-1s + NAD+ + sermorelin + generic ED + birth control) for single-platform users
  • 24-hour US board-certified physician response window

Where it loses points

  • Per-dose pricing tiers not transparently published on product pages — only 'starting from' prices visible
  • No explicit state-coverage list disclosed; FAQ confirms restrictions exist 'based on state' without enumeration
  • Medical director not named publicly
  • No published consultation fee disclosure — unclear whether physician visit is included in medication price
  • All sales final per FAQ ('Federal and State law do not allow medication returns')

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard